Cytokinetics (CYTK) Scheduled to Post Quarterly Earnings on Wednesday
Cytokinetics (NASDAQ:CYTK) is scheduled to announce its earnings results on Wednesday, February 14th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter.
Shares of Cytokinetics (NASDAQ:CYTK) opened at $8.60 on Tuesday. The company has a current ratio of 7.60, a quick ratio of 7.60 and a debt-to-equity ratio of 0.14. Cytokinetics has a fifty-two week low of $7.00 and a fifty-two week high of $17.20. The firm has a market capitalization of $463.41, a price-to-earnings ratio of -5.18 and a beta of 1.03.
Several equities research analysts recently weighed in on CYTK shares. HC Wainwright reaffirmed a “buy” rating and set a $26.00 price target on shares of Cytokinetics in a report on Friday, October 27th. Needham & Company LLC downgraded Cytokinetics from a “strong-buy” rating to a “buy” rating and decreased their price target for the stock from $22.00 to $12.00 in a report on Wednesday, November 29th. TheStreet downgraded Cytokinetics from a “c” rating to a “d” rating in a report on Friday, October 27th. Cantor Fitzgerald reissued a “hold” rating and issued a $10.00 target price on shares of Cytokinetics in a report on Wednesday, January 17th. Finally, JMP Securities reissued an “outperform” rating and issued a $13.00 target price (down previously from $17.00) on shares of Cytokinetics in a report on Tuesday, November 21st. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $17.91.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.